TEVOGEN BIO HOLDINGS INC (TVGN) Stock News

USA - Nasdaq - NASDAQ:TVGN - US88165K1016 - Common Stock

0.4378 USD

-0.01 (-2.93%)

Last: 12/10/2025, 8:21:42 PM

0.44 USD

+0 (+0.5%)

After Hours: 12/10/2025, 8:21:42 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TVGN Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Tevogen Bio Inc

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

a day ago - By: Tevogen Bio Inc

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

a month ago - By: Tevogen Bio Inc

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

a month ago - By: Tevogen Bio Inc

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

a month ago - By: Tevogen Bio Inc

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

a month ago - By: Tevogen Bio Inc

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

a month ago - By: Tevogen Bio Inc

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

a month ago - By: Tevogen Bio Inc

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

a month ago - By: Tevogen Bio Inc

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

a month ago - By: Tevogen Bio Inc

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

2 months ago - By: Tevogen Bio Inc

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

2 months ago - By: Tevogen Bio Inc

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

3 months ago - By: Tevogen Bio Inc

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

3 months ago - By: Tevogen Bio Inc

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

3 months ago - By: Tevogen Bio Inc

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

3 months ago - By: Tevogen Bio Inc

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

3 months ago - By: Tevogen Bio Inc

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

3 months ago - By: Tevogen Bio Inc

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

3 months ago - By: Tevogen Bio Inc

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

3 months ago - By: Tevogen Bio Inc

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

3 months ago - By: Tevogen Bio Inc

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

3 months ago - By: Tevogen Bio Inc

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

3 months ago - By: Tevogen Bio Inc

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

3 months ago - By: Tevogen Bio Inc

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

3 months ago - By: Tevogen Bio Inc

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

3 months ago - By: Tevogen Bio Inc

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

3 months ago - By: Tevogen Bio Inc

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

3 months ago - By: Tevogen Bio Inc

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

4 months ago - By: Tevogen Bio Inc

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

4 months ago - By: Tevogen Bio Inc

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

4 months ago - By: Tevogen Bio Inc

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

4 months ago - By: Tevogen Bio Inc

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

4 months ago - By: Tevogen Bio Inc

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

4 months ago - By: Tevogen Bio Inc

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

4 months ago - By: Tevogen Bio Inc

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

4 months ago - By: Tevogen Bio Inc

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

4 months ago - By: Tevogen Bio Inc

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

4 months ago - By: Tevogen Bio Inc

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

4 months ago - By: Tevogen Bio Inc

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

4 months ago - By: Tevogen Bio Inc

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum